Search clinical trials for: H5N1 Antigen

Total 1113 results

Seqirus

Completed

A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine

Influenza, Human

Estonia, Philippines
Biomedical Advanced Research and Development Authority

Completed

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Influenza A Virus, H5N1 Subtype

United States
Intercell USA, Inc.

Completed

Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine

Healthy

Austria, Belgium
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With AS03

Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Austria
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With MF59

Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

Influenza

Austria
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1

Influenza (Pandemic)

United States
Novavax
Department of Health and Human Services

Completed

A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2

Influenza (Pandemic)

United States
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age

Influenza

Germany
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
Biomedical Advanced Research and Development Authority
PPD

Completed

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

A/Vietnam/H5N1 Influenza Virus

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Development of Immune Globulin Treatment for Avian Flu

Influenza | Infectious Diseases | Avian Flu

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine

H5N1 Influenza

United States
Institute of Vaccines and Medical Biologicals,...
Department of Health and Human Services; Institut Pasteur; PATH; World Health Organization

Completed

Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1

Influenza A Subtype H5N1 Infection

Vietnam
Children's National Research Institute

Not yet recruiting

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (IMPACT)

Brain Tumor
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
National Institute of Allergy and Infectious Diseases...

Completed

Cell-Mediated Immune Responses to Influenza A/H5N1 Vaccine

Influenza

United States
Intercell USA, Inc.
Department of Health and Human Services

Completed

A/H5N1 Dose Ranging Study With Adjuvant Patch

Pandemic Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Hong Kong
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H5N1 Vaccine in the Elderly

Influenza

United States
VaxInnate Corporation

Completed

Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1in Adult - Aventis

Influenza

United States
Novavax

Completed

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

Pandemic Influenza

United States
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Children

Influenza

Australia
Seqirus

Completed

Study of a Pandemic Influenza Vaccine in Elderly Participants

Influenza

Australia
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
National Institute of Respiratory Diseases, Mexico
Hospital General Dr. Manuel Gea González; National Institute of Medical Sciences... and other collaborators

Not yet recruiting

Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico City (PREVALIOCDMX)

Acquired Immunodeficiency Syndrome | Cryptococcal Meningitis | Tuberculosis Infection | Histoplasmosis AIDS

Mexico
European Organisation for Research and Treatment...

Terminated

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Intraocular Melanoma

Belgium, Denmark
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults

Pandemic H5N1 Influenza

United States, Australia, Thailand
Intercell USA, Inc.
Department of Health and Human Services

Completed

A/H5N1/LT Dose Ranging Study

Pandemic Influenza

United States
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects

Pandemic H5N1 Influenza

United States, Australia, New Zealand, Thailand
Novartis Vaccines
Department of Health and Human Services

Completed

Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children

Pandemic H5N1 Influenza

United States, Thailand
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

Influenza

Italy
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Influenza

United States
GlaxoSmithKline

Completed

Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults

Influenza | Influenza Vaccines

Taiwan, Hong Kong, Thailand, Singapore
Butantan Institute

Completed

Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

Influenza | H7N9 Influenza

Brazil
Crucell Holland BV

Completed

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains

Influenza

Switzerland
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States

3

Subscribe